Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AQST vs AMPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AMPH Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

AMPH Overall Winner 6-Pillar Tally: AQST 1 – 5 AMPH Matrix Metrics: AQST 1 – 9 AMPH

As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas AMPH carries 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin).

  • Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY).
  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs AMPH
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23
AMPH NASDAQ Head-to-Head Winner
Amphastar Pharmaceuticals, Inc.
Pharmaceutical Preparations
$28.25
+0.5% 1D
Market Cap $1.2B
TTM Revenue $746M
Forward P/E 10.5x
Beta / 30D Vol 0.07β · 37% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 38.0 Fund 46.0 Flow 67.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.3% over 20 days), RSI 54
RSI-14: 54.3 · SMA20: $28.00 · SMA50: $26.51

6-Pillar Scorecard Institutional Category Breakdown (AQST 1 – 5 AMPH)

Columns: Metric · AQST · AMPH
1. Valuation Multiples AMPH
Forward P/E N/M 10.5x
Trailing P/E N/M 12.9x
PEG Ratio N/M 2.77x
EV / Revenue 8.9x 2.3x
2. Growth & Scale AMPH
Revenue Growth (YoY) -41.0% +8.2%
Earnings Growth (YoY) +0.0% +135.1%
TTM Revenue (USD) $49M $746M
Market Cap $465.7M $1.2B
3. Profitability & Quality AMPH
Gross Margin 65.3% 46.8%
Operating Margin -114.1% 18.7%
Net Profit Margin -162.3% 13.3%
Return on Equity (ROE) 0.0% 12.4%
4. Balance Sheet & Cash Flow AMPH
Cash Generation (TTM) -$41M $45M
Cash Flow Margin -83.3% 6.0%
Net Cash / Leverage $32M Net Cash $487M Net Debt (0.85x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 87.9% (64th %ile) 460.7% (100th %ile)
Put/Call OI Skew 0.98x (Balanced) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat AMPH
OpEx & R&D Intensity N/A 28.1% of Rev ($210M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (1) vs AMPH (9)
Institutional Metric AQST AMPH Criterion Row Edge
Market Capitalization
Scale
$465.7M $1.2B Larger Scale AMPH
Trailing P/E Ratio
Valuation
N/M 12.9x Lower Multiple AMPH
Forward P/E Ratio
Valuation
N/M 10.5x Lower Multiple AMPH
Revenue Growth (YoY)
Growth
-41.0% +8.2% Higher Growth AMPH
Operating Margin (TTM)
Profitability
-114.1% 18.7% Higher Margin AMPH
Net Profit Margin
Profitability
-162.3% 13.3% Higher Margin AMPH
Return on Equity (ROE)
Capital Efficiency
0.0% 12.4% Higher ROE AMPH
52-Week Range Position
Momentum
14% ($3–$7) 81% ($17–$31) Stronger Trend AMPH
Beta / 30D Volatility
Risk Regime
0.89β · 56% Vol 0.07β · 37% Vol Lower Realized Risk AMPH
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 48.8 / 100 (HOLD) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$49M $746M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% 46.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.9x EV/Rev 2.77x PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) $45M ($487M Net Debt (0.85x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AMPH +24.71 pp
AQST: -16.22% · AMPH: +8.49%
3M Horizon AMPH +59.19 pp
AQST: -27.92% · AMPH: +31.27%
6M Horizon AMPH +69.47 pp
AQST: -16.02% · AMPH: +53.45%
1Y Horizon AMPH +52.0 pp
AQST: -40.65% · AMPH: +11.35%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQST Revenue AMPH Revenue AQST Op. Margin AMPH Op. Margin Margin Leader
Q3 '25 $50M $770M -89.6% 13.2% AMPH
Q4 '25 $50M $730M -221.6% 19.4% AMPH
Q1 '26 $60M $680M -29.1% 8.0% AMPH
Q2 '26 $60M $740M -59.5% 21.6% AMPH
Q3 '26 $30M $830M -191.5% 24.5% AMPH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMPH CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 460.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AMPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AMPH Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.2B market capitalization and 18.7% operating margin.
OpEx & R&D Reinvestment 28.1% of Rev ($210M)
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs AMPH Key Questions & Quantitative Answers

As of Nov 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) is the stronger overall head-to-head candidate over Aquestive Therapeutics, Inc. (AQST) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AQST carries a Unified Composite Score of 62.9/100 (BUY) at $3.46 (N/M Forward P/E, -114.1% operating margin), whereas AMPH carries 48.8/100 (HOLD) at $28.25 (10.5x Forward P/E, 18.7% operating margin). Composite vs. Pillar Nuance: While AQST currently prints a higher short-term Unified Composite Score (62.9/100 BUY vs. AMPH 48.8/100 HOLD), AMPH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (18.7% vs. -114.1% operating margin) and revenue trajectory (+8.2% vs. -41.0% YoY). Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile AMPH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMPH leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with AMPH at +8.2% YoY revenue growth and +135.1% YoY earnings growth on $746M TTM revenue (46.8% gross margin, 18.7% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), AQST cumulative revenue shifted -40.0% while AMPH shifted +7.8%. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus 28.1% of Rev ($210M) (0 disclosures) for AMPH.

AMPH screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas AMPH trades at 10.5x Forward P/E, 12.9x Trailing P/E, 2.77x PEG, and 2.3x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus AMPH (12.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, AMPH carries 460.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.07β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.